600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
| Autor: | Elez Fernandez, M.E., Rosello Keranen, S., Paez, D., Jiménez Castro, J., Rivera Herrero, F., Ruiz-Casado, A., Riesco Martinez, M.C., Montagut Viladot, C., Coupez, D., Ducreux, M.P., Loly, C., Martin-Babau, J., Prenen, H., van den Eynde, M., Borg, C., Cuyle, P-J., de Haar-Holleman, A., Raimbourg, J., Bechar, N., Tabernero, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S480-S481 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|